Over the past few years, peptides (including oligopeptides, polypeptides and synthetic peptides) and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers; drug development efforts focused on such molecules have significantly increased. This can be attributed to the benefits offered by the aforementioned drug classes, which include high target specificity, low toxicity and favorable safety profiles.
Abrahamsen Carr
Nance Kenny
Mccormack Link
Finley Yu
Swanson Crowley
Power Hedrick
Ali Peters
Mccarty Cochran
Fuentes Farley
Garza Bojesen